SCHEMBL440915

SCHEMBL440915

COc1cc(CNC(=O)c2cc(-c3ccc(Cl)cc3)c(OC(C)C(F)(F)F)nn2)on1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.38
TP53 P04637 2/20 0.38
THRB P10828 2/20 0.38
HTT P42858 2/20 0.38
JAK2 O60674 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412022 1.00 NPC1 (0.44) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL411097 0.87 NPC1 (0.43) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL444341 0.86 NPC1 (0.45) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL411573 0.86 NPC1 (0.45) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL410622 0.86 CNR1 (0.45) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL441620 0.86 CNR1 (0.45) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL442076 0.83 NPC1 (0.43) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL412187 0.83 NPC1 (0.43) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL412251 0.79 NPC1 (0.53) NPC1RAB9ALMNASMN1; SMN2POLB
SCHEMBL411019 0.78 MAP4K4 (0.38) SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2613785-B1 HETEROARYLMETHYL AMIDES HOFFMANN LA ROCHE (CH) 2015-07-29 EP claimed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 US claimed
EP-2613785-B1 HETEROARYLMETHYL AMIDES HOFFMANN LA ROCHE (CH) 2015-07-29 EP disclosed
US-9090599-B2 Heteroarylmethyl amides HOFFMANN-LA ROCHE INC. (US) 2015-07-28 US disclosed
US-20140194436-A1 HETEROARYLMETHYL AMIDES HOFFMANN-LA ROCHE INC. (US) 2014-07-10 US disclosed
US-8729105-B2 Heteroarylmethyl amides HOFFMANN LA-ROCHE INC. (US) 2014-05-20 US disclosed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194436-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR NPC1 16/4885RAB9A 840/4885LMNA 886/4885
US-20120065212-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR NPC1 16/4885RAB9A 840/4885LMNA 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.